Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor

Diabetes and Vascular Disease Research

Volumn 12, Issue 2, 2015, Pages 101-110

  Lapuerta, Pablo ^a   Zambrowicz, Brian ^a   Strumph, Paul ^a   Sands, Arthur ^a,b  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

diabetes mellitus; diabetes mellitus type 2; glucagon like peptide 1; LX4211; sodium glucose transporter 1; sodium glucose transporter 2; sotagliflozin; type 1

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSIDE; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN;

AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTENSION; IC50; INSULIN DEPENDENT DIABETES MELLITUS; MODERATE RENAL IMPAIRMENT; MYCOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; SEVERE RENAL IMPAIRMENT; URINARY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DEVELOPMENT; DRUG EFFECTS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; URINARY EXCRETION;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; GLYCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; RENAL ELIMINATION; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84923510983     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114563304     Document Type: Article

References (42)

1. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994 ; 93: 397-404
2. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005 ; 54: 3427-3434
3. RosebraughCJ. Dapagliflozin new drug application approval letter, 2014, http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/202293Orig1s000ltr.pdf (accessed 5 September 2014).
4. RosebraughCJ. Canagliflozin new drug application approval letter, 2013, http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2013/204042Orig1s000ltr.pdf (accessed 5 September 2014).
5. RosebraughCJ. Empagliflozin new drug application approval letter, 2013, http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/204629Orig1s000ltr.pdf (accessed 5 September 2014).
6. Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987 ; 330: 379-381
7. Dyer J, Wood IS, Palejwala A, et al. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol. 2002 ; 282: G241 - G248
8. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011 ; 91: 733-794
9. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol. 2003 ; 3: 563-570
10. Powell D, DaCosta C, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2103 ; 304: E117 - E130
11. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 ; 92: 158-169
12. Powell D, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 ; 345: 250-259
13. Powell D, DaCosta C, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther. 2014 ; 350: 232-242
14. The Woodlands, TX: Lexicon Pharmaceuticals, Inc. ; 2010 :
15. Janssen Research & Development, LLC. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus, 11December2012, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf (accessed 13 September 2014).
16. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014 ; 3: 212-262
17. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther. 2013 ; 35: 1162-1173
18. Zambrowicz B, Ding Z, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013 ; 35: 273-285
19. Lapuerta P, Rosenstock J, Zambrowicz B, et al. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy. Clin Cardiol. 2013 ; 36: 367-371
20. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2, in type 2 diabetes on metformin monotherapy. Diabetes Care. 2015 ;:
21. Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I, Sands A, Powell D. LX4211 Reduces Postprandial Glucose in Patients with Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion. Clin Ther. :
22. The Woodlands, TX: Lexicon Pharmaceuticals, Inc. ; 2014 :
23. US Food and Drug Administration (FDA). Full prescribing information, FARXIGA (dapagliflozin) tablets, for oral use, http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202293s003lbl.pdf (accessed 14 September 2014).
24. US Food and Drug Administration (FDA). Full prescribing information, INVOKANA (canagliflozin) tablets, for oral use, http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204042s002lbl.pdf (accessed 14 September 2014).
25. US Food and Drug Administration (FDA). Full prescribing information, JARDIANCE® (empagliflozin) tablets, for oral use, http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204629s000lbl.pdf (accessed 14 September 2014).
26. The Woodlands, TX: Lexicon Pharmaceuticals, Inc. ; 2014 :
27. The Woodlands, TX: Lexicon Pharmaceuticals, Inc. ; 2014 :
28. Chillarón JJ, Flores Le-Roux J, Benaiges D. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014 ; 63: 181-187
29. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002 ; 45: 937-948
30. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007 ; 356: 1842-1852
31. Feltbower RG, Bodansky HJ, Patterson CC. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care. 2008 ; 31: 922-926
32. Scirica BM, Bhatt DL, Braunwald E. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 ; 369: 1317-1326
33. White WB, Cannon CP, Heller SR. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 ; 369: 1327-1335
34. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke. 1980 ; 11: 14-21
35. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999 ; 354: 617-621
36. Ceriello A, Davidson J, Hanefeld M. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis. 2006 ; 16: 453-456
37. Ferdinand KC, White WB, Calhoun DA. Effects of the once-weekly glucagon-like Peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 ; 64: 731-737
38. Kim M, Platt MJ, Shibasaki T. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013 ; 19: 567-575
39. Goldring W, Welsh C. The effects on renal activity of the oral administration of phlorizin in man. J Clin Invest. 1934 ; 13: 749-752
40. Wang T, Gou Z, Wang F, et al. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS ONE. 9: e103798
41. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002 ; 347: 1256-1261
42. Apperloo AJ, De Zeeuw D, De Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997 ; 51: 793-797